Selected article for: "attack complex and MAC attack complex"
Author: Sun, Shihui; Jiang, Yuting; Wang, Renxi; Liu, Chenfeng; Liu, Xiaoling; Song, Nianping; Guo, Yan; Guo, Renfeng; Du, Lanying; Jiang, Shibo; Li, Yan; Qiu, Zewu; Zhao, Guangyu; Zhou, Yusen
Title: Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application*
  • Document date: 2018_4_13
    • ID: 6ztwho9k_7
    Snippet: IFX-1 (NCT01319903; developed by InflaRx GmbH, Jena, Germany), a highly potent neutralizing antihuman C5a monoclonal antibody that leaves the formation of the membrane attack complex (MAC), is in various phase II clinical trials (www.inflarx.de). In this study, we tested whether IFX-1 is an effective way to alleviate ALI by blocking systemic inflammatory responses in a monkey model of paraquat poisoning. The results showed that IFX-1 alleviated A.....
    Document: IFX-1 (NCT01319903; developed by InflaRx GmbH, Jena, Germany), a highly potent neutralizing antihuman C5a monoclonal antibody that leaves the formation of the membrane attack complex (MAC), is in various phase II clinical trials (www.inflarx.de). In this study, we tested whether IFX-1 is an effective way to alleviate ALI by blocking systemic inflammatory responses in a monkey model of paraquat poisoning. The results showed that IFX-1 alleviated ALI and reduced levels of systemic inflammation. Importantly, in vitro data indicated that IFX-1 effectively blocks granulocytes activation by plasma from paraquat patients. Thus, targeting C5a might be a promising strategy for adjunctive treatment of ALI induced by toxic agents, such as paraquat.

    Search related documents:
    Co phrase search for related documents
    • adjunctive treatment and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8
    • adjunctive treatment and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • adjunctive treatment and monoclonal antibody: 1
    • ALI alleviate and inflammatory response: 1
    • ALI alleviate and paraquat poisoning: 1
    • attack complex and clinical trial: 1
    • attack complex and inflammatory response: 1, 2
    • attack complex and MAC attack complex: 1, 2, 3, 4, 5, 6, 7, 8
    • attack complex and membrane MAC attack complex: 1, 2, 3, 4, 5, 6, 7, 8
    • attack complex and membrane MAC attack complex formation: 1, 2, 3, 4
    • attack complex and monoclonal antibody: 1, 2
    • clinical trial and ii clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and MAC attack complex: 1
    • clinical trial and membrane MAC attack complex: 1
    • clinical trial and membrane MAC attack complex formation: 1
    • clinical trial and monoclonal antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • effectively block and inflammatory response: 1
    • effectively block and monoclonal antibody: 1, 2, 3, 4